Sweet Success Story: How Remote Support Helped Amanda Cut Her GRI by More Than Half

Proactive diabetes care isn’t just about reacting to numbers — it’s about building relationships. At SweetSpot, we partner with endocrinology practices to stay meaningfully connected with patients between visits to deliver consistent, compassionate care that drives better outcomes. 

When Amanda enrolled in the SweetSpot program, she had been managing her type 2 diabetes for over two decades — and she was stuck. Despite years of treatment, she was skeptical of making medication changes. But with consistent remote support from her provider and SweetSpot CDCES, Amanda’s Time in Range increased from just 1% to 57%, and she was able to cut her Glycemia Risk Index (GRI) in half. Her journey reflects the power of trust-building and persistent support. 

A Closer Look: Why Amanda Was Flagged for Support  

Amanda was enrolled in the SweetSpot program through her endocrinologist’s office. Our clinical team quickly flagged her profile due to several high-risk indicators: very low Time in Range, an elevated GRI, and patterns suggesting limited engagement and poor adherence to diabetes medications. 

During her first call with a SweetSpot CDCES, Amanda was honest: she felt stuck and disheartened. After more than 20 years living with type 2 diabetes and trying many medications — often with frustrating side effects — she was wary of making changes.

Her concerns were understandable. Amanda’s health history is complex, including a past myocardial infarction (MI), congestive heart failure (CHF), liver failure, and Thyroid cancer. 

These conditions made diabetes management more complicated — and made Amanda hesitant about adjusting her medication regimen. But she was open to a conversation. And that was the start. 

Empathetic Communication Made the Difference  

Pairing Clinical Expertise with Human Connection  SweetSpot assigned a dedicated CDCES to work with Amanda. Over a series of phone calls, this clinician provided: 

• Medication education, helping Amanda understand the purpose and potential of new treatments 

• Support in understanding insulin timing and how to safely manage hypoglycemia 

• Guidance on what to expect from different therapies, so she could approach her provider visits feeling confident and informed 

We used regular phone check-ins, personalized follow-ups, and text reminders to stay engaged. When Amanda faced barriers — like prescription delays or device challenges — our team stepped in to help troubleshoot. 

This was not a one-and-done case. It took months of consistent support to build rapport, answer questions, and help Amanda advocate for herself. 

At one point, Amanda expressed interest in Mounjaro after hearing about it from another specialist. Our team discussed it with her and encouraged her to revisit it with her provider. That conversation helped open a door — one Amanda had previously been afraid to walk through. 

Results That Speak for Themselves 

Over the course of six months, Amanda’s GRI dropped dramatically from 100 to 39 —  a 56% reduction in glycemic risk. Clinically, this suggests fewer dangerous highs and lows, more time in safe ranges, and lower risk of complications, hospitalizations, and daily disruption.  

A GRI below 50 is generally considered a safer zone and is a common benchmark in diabetes technology research. Amanda moved from a very high-risk range to a moderate and much safer one. 

Amanda’s Time in Range also increased from just 1% to 57%, and she was now spending 0% of time in hypoglycemia, an especially meaningful outcome given her elevated risk due to CHF. 

Amanda’s quality of life had transformed as well. With her provider’s close monitoring and SweetSpot’s ongoing support, she has: 

• Safely stopped using insulin 

• Reported significantly more energy 

• Returned to regular exercise 

• Engaged more proactively in her diabetes management than she had in years  

The Turning Point: Being Heard 

The key intervention in Amanda’s story wasn’t just a new medication — it was feeling heard. SweetSpot’s approach centered on meeting her where she was, clinically and emotionally. 

With each conversation, Amanda felt more empowered to take ownership of her care. The consistency of a familiar voice, backed by expert guidance and real-time data, helped her shift from resistance to renewed hope. 

Why Amanda's Story Matters 

This case isn’t unique — it’s exactly why SweetSpot exists. 

Amanda’s experience highlights the value of combining continuous data monitoring with human support. Patients with multiple comorbidities and deep-rooted hesitations often need more than check-ins every few months. They need someone who understands the clinical landscape and knows how to listen. That’s what SweetSpot delivers. And that’s what keeps us going. 

Want to see how SweetSpot can support your practice and patients? Reach out to us at info@sweetspot.health 

---

SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care.

SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot’s virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes.

Additionally, SweetSpot’s automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially profitable.